Previous studies have shown that CD97 and CD55 are involved in the dedifferentiation, migration, invasiveness and metastasis of tumours.
| Inventor | Institute |
|---|---|
| D.L. Hardie | University of Birmingham |
| Cat. #: | 152149 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cancer;Cell biology;Immunology |
| Application: | FACS ; IP |
| Target: | CD55 (CD97 ligand) |
| Reactivity: | Human |
| Clone: | BU14 |
| Host: | Mouse |
| Class: | Monoclonal |
| Alternate name: | CD55 Molecule (Cromer Blood Group); CD55 Molecule; Decay Accelerating Factor For Complement (Cromer Blood Group); CD55 Antigen; DAF; CR; Decay Accelerating Factor For Complement; CROM; TC |
|---|---|
| Product description: | CD97 is a member of the epidermal growth factor-seven transmembrane family. It affects tumour aggressiveness by binding its cellular ligand CD55 and exhibits adhesive properties. Previous studies have shown that CD97 and CD55 are involved in the dedifferentiation, migration, invasiveness and metastasis of tumours. |
| Conjugation: | Unconjugated |
| Isotype: | IgG1 |
| Target background: | CD97 is a member of the epidermal growth factor-seven transmembrane family. It affects tumour aggressiveness by binding its cellular ligand CD55 and exhibits adhesive properties. Previous studies have shown that CD97 and CD55 are involved in the dedifferentiation, migration, invasiveness and metastasis of tumours. |
|---|
| Format: | Liquid |
|---|---|
| Shipping conditions: | Dry ice |
| References: |
Ling et al. 1998. Clin Exp Immunol. 113(3):360-6. PMID: 9737663. Origin and properties of soluble CD21 (CR2) in human blood. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151025 | Anti-Vascular endothelium [10] |
Key Info
Anti-Vascular endothelium [10]
|
View Tool | |||||||||||||||||||
| 151026 | Anti-FCGR1 [10.1] mAb |
Key Info
Anti-FCGR1 [10.1] mAb
|
View Tool | |||||||||||||||||||
| 151027 | Anti-HSVICP8 [10A3] |
Key Info
Anti-HSVICP8 [10A3]
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
| 151028 | Anti-Cytochrome P450 2C2, 2B1/2 [h7] |
Key Info
Anti-Cytochrome P450 2C2, 2B1/2 [h7]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.